We are live on ! Find out more
RPRX

Repros Therapeutics Inc.
RPRX

Delisted

RPRX was delisted on the 31st of January, 2018.

Back to rankings

43 hedge funds and large institutions have $9.45M invested in Repros Therapeutics Inc. in 2016 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 16 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

639% more call options, than puts

Call options by funds: $1.07M | Put options by funds: $145K

19% more capital invested

Capital invested by funds: $7.91M → $9.45M (+$1.54M)

19% less funds holding

Funds holding: 53 → 43 (-10)

63% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 16

67% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 15

Holders
43
Holders Change
-10
Holders Change %
-18.87%
% of All Funds
1.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
6
Reduced
16
Closed
15
Calls
$1.07M
Puts
$145K
Net Calls
+$927K
Net Calls Change
+$792K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$737K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$335K
3
BIT
BlackRock Institutional Trust
California
+$256K
4
Simplex Trading
Simplex Trading
Illinois
+$165K
5
ARTA
A.R.T. Advisors
New York
+$65.8K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.18M
2
SCM
Sarissa Capital Management
Connecticut
-$970K
3
GCM
Gruss Capital Management
New York
-$582K
4
Millennium Management
Millennium Management
New York
-$403K
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$232K
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
26
Wells Fargo
California
$9K +$190 +99 +2%
Creative Planning
27
Creative Planning
Kansas
$8K – – –
BA
28
BlackRock Advisors
Delaware
$7K – – –
BIM
29
BlackRock Investment Management
Delaware
$7K – – –
BFEC
30
Benjamin F. Edwards & Company
Missouri
$4K – – –
Deutsche Bank
31
Deutsche Bank
Germany
$3K -$83.9K -43,731 -95%
BWP
32
Baldwin Wealth Partners
Massachusetts
$3K – – –
Citigroup
33
Citigroup
New York
$2K -$48 -25 -2%
Bank of Montreal
34
Bank of Montreal
Ontario, Canada
$2K – – –
Manulife (Manufacturers Life Insurance)
35
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$2K – – –
KF
36
Krilogy Financial
Missouri
$1K – – –
Walleye Trading
37
Walleye Trading
New York
$1K +$1.73K +900 New
SCM
38
Sarissa Capital Management
Connecticut
– -$970K -1,001,000 Closed
GCM
39
Gruss Capital Management
New York
– -$582K -600,000 Closed
Millennium Management
40
Millennium Management
New York
– -$403K -415,520 Closed
D.E. Shaw & Co
41
D.E. Shaw & Co
New York
– -$232K -239,548 Closed
Citadel Advisors
42
Citadel Advisors
Florida
– -$60.5K -31,535 Closed
VKH
43
Virtu KCG Holdings
New York
– -$28K -28,386 Closed
GCP
44
GSA Capital Partners
United Kingdom
– -$27K -27,931 Closed
Acadian Asset Management
45
Acadian Asset Management
Massachusetts
– -$25K -26,116 Closed
GC
46
Guggenheim Capital
Illinois
– -$20K -20,254 Closed
Nomura Holdings
47
Nomura Holdings
Japan
– -$17K -17,900 Closed
HSBC Holdings
48
HSBC Holdings
United Kingdom
– -$15K -15,000 Closed
AL
49
Airain Ltd
Guernsey
– -$13K -13,690 Closed
UBS Group
50
UBS Group
Switzerland
– -$8.27K -4,311 -98%
1
2
3

RPRX Hedge Fund Activity: Q2 2016 in Review

43 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Repros Therapeutics Inc. (RPRX) for Q2 2016, worth a combined $9.45M — up 19% from $7.91M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of RPRX and 5 opened new positions — a net loss of 10 holders — while 16 trimmed existing stakes and 6 added.

The largest buyer was Renaissance Technologies, adding an estimated $737K. The largest seller was Fidelity Investments, cutting an estimated $1.18M.

  • 43 institutional investors held Repros Therapeutics Inc. (RPRX) as of Q2 2016, down from 53 in Q1 2016.
  • Funds reported $9.45M of Repros Therapeutics Inc. stock for Q2 2016, up 19% quarter-over-quarter.
  • 5 funds opened new Repros Therapeutics Inc. positions in Q2 2016 and 15 closed out, a net change of -10 holders.
  • The largest Repros Therapeutics Inc. buyer in Q2 2016 was Renaissance Technologies, an estimated $737K added.
  • The largest Repros Therapeutics Inc. seller in Q2 2016 was Fidelity Investments, an estimated $1.18M sold.

Based on aggregated 13F filings for Q2 2016.